BCV
ALNY icon

Banque Cantonale Vaudoise’s Alnylam Pharmaceuticals ALNY Stock Holding History

Banque Cantonale Vaudoise’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.2M Buy
7,303
+1,325
+22% +$400K 0.3% 60
2026
Q1 		$1.98M Sell
5,978
-5,059
-46% -$1.72M 0.07% 247
2025
Q4 		$4.39M Buy
11,037
+6,177
+127% +$2.73M 0.16% 122
2025
Q3 		$2.22M Sell
4,860
-883
-15% -$360K 0.08% 234
2025
Q2 		$1.87M Buy
5,743
+2,015
+54% +$558K 0.08% 247
2025
Q1 		$1.01M Buy
+3,728
New +$958K 0.04% 354
2024
Q3 		$1.53M Buy
+5,560
New +$1.45M 0.06% 269
2023
Q4 		– Sell
-2,058
Closed -$365K – 1019
2023
Q3 		$365K Sell
2,058
-2,842
-58% -$542K 0.02% 545
2023
Q2 		$931K Buy
4,900
+2,100
+75% +$416K 0.04% 361
2023
Q1 		$561K Hold
2,800
– – 0.03% 427
2022
Q4 		$666K Sell
2,800
-3,500
-56% -$747K 0.03% 389
2022
Q3 		$1.26M Buy
6,300
+3,500
+125% +$668K 0.07% 268
2022
Q2 		$408K Hold
2,800
– – 0.02% 545
2022
Q1 		$458K Hold
2,800
– – 0.02% 582
2021
Q4 		$475K Sell
2,800
-300
-10% -$55.8K 0.02% 597
2021
Q3 		$585K Hold
3,100
– – 0.03% 526
2021
Q2 		$526K Hold
3,100
– – 0.02% 580
2021
Q1 		$438K Buy
3,100
+1,700
+121% +$256K 0.02% 575
2020
Q4 		$182K Sell
1,400
-2,400
-63% -$320K 0.01% 749
2020
Q3 		$553K Buy
3,800
+1,001
+36% +$142K 0.04% 408
2020
Q2 		$414K Buy
2,799
+299
+12% +$40.3K 0.03% 439
2020
Q1 		$272K Hold
2,500
– – 0.02% 541
2019
Q4 		$288K Buy
+2,500
New +$249K 0.02% 626

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Banque Cantonale Vaudoise's ALNY Position: Q2 2026 in Review

Banque Cantonale Vaudoise increased its Alnylam Pharmaceuticals (ALNY) stake by 22% in Q2 2026, buying an estimated $400K and bringing the position to 7,303 shares worth $2.2M. The position accounts for 0.3% of the portfolio, ranked #60.

Banque Cantonale Vaudoise first reported a position in ALNY in Q4 2019 and has held it in 23 quarters since. The position peaked at $4.39M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Banque Cantonale Vaudoise held 7,303 shares of Alnylam Pharmaceuticals worth $2.2M as of Q2 2026.
  • Banque Cantonale Vaudoise bought 1,325 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $400K.
  • Alnylam Pharmaceuticals made up 0.3% of Banque Cantonale Vaudoise's portfolio in Q2 2026, its #60 holding.
  • Banque Cantonale Vaudoise first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 23 quarters since.
  • Banque Cantonale Vaudoise's Alnylam Pharmaceuticals position peaked at $4.39M in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2026, filed 31 Jul 2026.